Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives — Huib A.A.M. van Vliet (2008) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives
Shared by
Frits R. Rosendaal
Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives
Letter
2008
English
Authors
+1 more
HV
Huib A.A.M. van Vliet
Frits R. Rosendaal
Leiden University
JR
Jan Rosing
Abstract
1 min read
No abstract is provided for this article.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2012
Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives
M. RAPS
,
Frans M. Helmerhorst
,
Kathrin Fleischer
,
Stella Thomassen
,
Frits R. Rosendaal
,
Jan Rosing
,
Bart E.P.B. Ballieux
,
Huib van Vliet
Journal of Thrombosis and Haemostasis
Article
2012
Sex hormone‐binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives
Bernardine H. Stegeman
,
Frans M. Helmerhorst
,
Hans L. Vos
,
Frits R. Rosendaal
,
Astrid van Hylckama Vlieg
Journal of Thrombosis and Haemostasis
Letter
2012
Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone‐binding globulin levels in premenopausal women
Bernardine H. Stegeman
,
M. RAPS
,
Frans M. Helmerhorst
,
Hans L. Vos
,
Hubertus A.A.M. van Vliet
,
Frits R. Rosendaal
,
Astrid van Hylckama Vlieg
Journal of Thrombosis and Haemostasis
Article
1998
Venous and arterial thromboembolism in users of oral contraceptives and hormone replacement therapy
Frits R. Rosendaal
Letter
1999
Venous thromboembolism and oral contraceptives
Kitty W.M. Bloemenkamp
,
Frits R. Rosendaal
,
Frans M. Helmerhorst
,
Jan P. Vandenbroucke
The Lancet
Discussion(0)
No comments yet. Be the first to comment.